Background/Aim: To assess safety of hypo-fractionated radiotherapy( HyRT) followed by low dose radiation therapy( LD-FRT) plus Temozolomide( TMZ) in naive unresectable Glioblastoma. Methods: Patients( ECOG < 2,age ...Background/Aim: To assess safety of hypo-fractionated radiotherapy( HyRT) followed by low dose radiation therapy( LD-FRT) plus Temozolomide( TMZ) in naive unresectable Glioblastoma. Methods: Patients( ECOG < 2,age > 18) undergone to biopsy or with gross residual tumor after surgery were enrolled. HyRT( 30 Gy in ten fraction) plus TMZ was administered. From the second adjuvant cycle of TMZ,patients received LD-FRT( 0. 40 Gy twice daily over 5 days,every 28 days) for two cycles. The primary endpoints were safety and toxicity. Moreover we analyzed response,overall survival( OS) and progression-free survival( PFS). Results: Twenty patients were enrolled. Median dose of LD-FRT was 12 Gy. All toxicities were reversible. Four out of 20 patients had Partial Response( PR)and 6 experienced a stable disease( SD). Median OS and PFS were 14 and 11 months,respectively.Conclusions: HyRT followed by LD-FRT plus TMZ is safe and shows good clinical outcomes. A new study is ongoing.展开更多
文摘Background/Aim: To assess safety of hypo-fractionated radiotherapy( HyRT) followed by low dose radiation therapy( LD-FRT) plus Temozolomide( TMZ) in naive unresectable Glioblastoma. Methods: Patients( ECOG < 2,age > 18) undergone to biopsy or with gross residual tumor after surgery were enrolled. HyRT( 30 Gy in ten fraction) plus TMZ was administered. From the second adjuvant cycle of TMZ,patients received LD-FRT( 0. 40 Gy twice daily over 5 days,every 28 days) for two cycles. The primary endpoints were safety and toxicity. Moreover we analyzed response,overall survival( OS) and progression-free survival( PFS). Results: Twenty patients were enrolled. Median dose of LD-FRT was 12 Gy. All toxicities were reversible. Four out of 20 patients had Partial Response( PR)and 6 experienced a stable disease( SD). Median OS and PFS were 14 and 11 months,respectively.Conclusions: HyRT followed by LD-FRT plus TMZ is safe and shows good clinical outcomes. A new study is ongoing.
